B. Riley lowered the firm’s price target on Hyperfine to $1.30 from $1.70 and keeps a Buy rating on the shares. The company’s Q4 sales and 2024 guidance disappointed, the analyst tells investors in a research note. The firm awaits accelerated adoption after demonstrating clinical evidence from the CARE-PMR trial by the end of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
